CORE C. IMMUNE ASSAY, FLOW CYTOMETRY AND GENE PROFILING This Core will support the Projects of this program project by providing flow cytometry and gene expression profiling services and by performing in vitro functional assays to monitor the immune status of subjects participating in clinical trials. For the clinical trial described in Project 1, the Core will be used to document the development of T cell tolerance to donor or host alloantigens, and assess the ability of the reconstituted patients to mount an immune response to newly introduced as well as recall antigens. For all four Projects the Core will provide flow cytometry based cellular phenotype analysis including the determination of adequate host T cell depletion and the monitoring of T cell recovery following hematopoiefic progenitor cell transplantation for the patients in the clinical trials (Project 1) and for cell phenotype analysis and purification (Projects 2-4). The Core will also provide gene expression profiling to idenfify genes associated with clinical immune tolerance in transplant recipients (Project 1), identify specific cell types expressing these genes (Projects 1 and 4) or identify genes that are differentially expressed in functional subsets of dendritic cells (Project 4).
Some patients tolerate transplanted organs without the need for dangerous immunosuppressive drugs. The goal of this Core is to support the effort in all of the Projects to identify the cells, genes and substances required for this tolerant state. If we are successful, future organ transplant recipients may no longer need to be treated with such toxic drugs.
|Kawai, Tatsuo; Leventhal, Joseph; Wood, Kathryn et al. (2018) Summary of the Third International Workshop on Clinical Tolerance. Am J Transplant :|
|Scandling, John D; Busque, Stephan; Lowsky, Robert et al. (2018) Macrochimerism and clinical transplant tolerance. Hum Immunol 79:266-271|
|Pierini, Antonio; Nishikii, Hidekazu; Baker, Jeanette et al. (2017) Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun 8:15068|
|Mavers, Melissa; Maas-Bauer, Kristina; Negrin, Robert S (2017) Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 8:900|
|Hongo, David; Tang, Xiaobin; Zhang, Xiangyue et al. (2017) Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood 129:1718-1728|
|Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125|
|Simonetta, Federico; Alvarez, Maite; Negrin, Robert S (2017) Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol 8:465|
|Zhang, Hong; Gregorio, Josh D; Iwahori, Toru et al. (2017) A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes. Proc Natl Acad Sci U S A 114:1988-1993|
|Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634|
|Revelo, Xavier S; Ghazarian, Magar; Chng, Melissa Hui Yen et al. (2016) Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance. Cell Rep 16:717-30|
Showing the most recent 10 out of 70 publications